Shared Disease Mechanisms in NAFLD and Metabolic Syndrome Shared Disease Mechanisms in NAFLD and Metabolic Syndrome

Advancements in our understanding of the interactions between NAFLD and metabolic syndrome-associated disorders could help better define therapeutic targets.Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Related Links:

In conclusion, a polypharmacology approach of combining established, prolongevity drug inhibitors of specific nodes may be the most effective way to target the nutrient-sensing network to improve late-life health. Deletion of p38α in Neurons Slows Neural Stem Cell Decline and Loss of Cognitive Function in Mice https://www.fightaging.org/archives/2019/10/deletion-of-p38%ce%b1-in-neurons-slows-neural-stem-cell-decline-and-loss-of-cognitive-function-in-mice/ Researchers here provide evidence for p38α to be involved in the regulation of diminished neural stem cell activity with age. It is thought...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Abstract NAFLD is very prevalent worldwide, and is associated with insulin resistance and metabolic syndrome. Stress is physiological and biological response to maintain homeostasis of body against stressors while severe stress response is an important contributor to various illnesses including metabolic syndrome and brain disorders. We have evaluated the effects of intermittent restraint stress on NAFLD in a HFD-fed mouse model. C57/BL6 mice had free access to a 60% HFD for 8 weeks, with or without intermittent restraint stress (3 h) conducted 3 times a week. HFD administration increased fat accumulation in liver...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - Category: Physiology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research
This study aimed to investigate the effects of a 12-week multicomponent intervention program in markers of metabolic syndrome and NAFLD in Brazilian overweight/obese low-income school-aged children.MethodsThis quasi-experimental study comprised overweight/obese school-aged children, aged 7 –13 years. The participants were assigned to intervention (n = 17) or control group (n = 18). The multicomponent intervention was developed during 12 weeks, consisting of exercise sessions (twice/week; 1 h), nutritional education sessions (once/month), and parental support (twice/week). The fol...
Source: Sport Sciences for Health - Category: Sports Medicine Source Type: research
Metabolic syndrome, characterized by central obesity, hypertension, and hyperlipidemia, increases the morbidity and mortality of cardiovascular disease, type 2 diabetes, nonalcoholic fatty liver disease, and other metabolic diseases. It is well known that insulin resistance, especially hepatic insulin resistance, is a risk factor for metabolic syndrome. Current research has shown that hepatic fatty acid accumulation can cause hepatic insulin resistance through increased gluconeogenesis, lipogenesis, chronic inflammation, oxidative stress and endoplasmic reticulum stress, and impaired insulin signal pathway. Mitochondria ar...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionThere is low awareness of NAFLD among individuals with hepatic steatosis on imaging, even among those with metabolic risk factors. These findings highlight an opportunity to raise public and practitioner awareness of NAFLD with the goal of increasing diagnosis and implementing early treatment strategies.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
CONCLUSION: In this study, we demonstrate that risk factors for NAFLD and LF in the IBD population do not differ from those in the general population. PMID: 31602167 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
A newly developed drug for treating metabolic syndrome safely reduces plasma triglycerides and LDL cholesterol, and reverses NAFLD and liver insulin resistance, according to a study published inScience Translational Medicine.MedicalXpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
CONCLUSION: Thrombocytopenia is an infrequent event in NAFLD patients without cirrhosis and is related with male sex and higher hemoglobin levels. PMID: 31575467 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Obesity and its complications, which affect myriad organ systems, continue to be major worldwide public health problems in adults and children.1 Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and the metabolic syndrome that encompasses insulin resistance, dyslipidemia, and hypertension. The prevalence of NAFLD in children varies widely and is dependent on the method of diagnosis, age, sex, and ethnicity, but the estimated global prevalence is 7.6% in the general pediatric population and 34.2% in obese children.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Editorial Source Type: research
In nonhuman trials, the drug has been shown to safely reduce plasma triglycerides and “bad” LDL cholesterol, and to reverse nonalcoholic fatty liver disease.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
More News: Drugs & Pharmacology | Gastroenterology | Health | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD)